Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis

Modern Rheumatology

Volumn 25, Issue 4, 2015, Pages 615-620

  Tayfur, Asli Celebi ^a   Topaloglu, Rezan ^a   Gulhan, Bora ^a   Bilginer, Yelda ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bisphosphonate; Dystrophic calcinosis; Immunosuppressive treatment; Intravenous immunoglobulin; Juvenile dermatomyositis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; PAMIDRONIC ACID; PREDNISOLONE; RISEDRONIC ACID; RITUXIMAB; STEROID; BONE DENSITY CONSERVATION AGENT;

ARTHRALGIA; ARTICLE; CALCINOSIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; FEMALE; GROWTH RETARDATION; HEART FAILURE; HEPATOMEGALY; HUMAN; INFANT; JOINT CONTRACTURE; JUVENILE DERMATOMYOSITIS; LIMITED MOBILITY; MUSCLE WEAKNESS; OSTEOPOROSIS; PLASTIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RHEUMATOID ARTHRITIS; SCHOOL CHILD; SKIN DISEASE; SKIN ULCER; SPLENOMEGALY; CASE REPORT; COMPLICATION; DERMATOMYOSITIS; DISEASE COURSE; METABOLISM; RETROSPECTIVE STUDY;

BONE DENSITY CONSERVATION AGENTS; CALCINOSIS; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; INFANT; RETROSPECTIVE STUDIES;

EID: 84934919639     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.988197     Document Type: Article

References (34)

1. Rider LG, Lindley CB, Cassidy JT. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. pp. 375–413.
2. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic infl ammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.
3. Lowry CA, Pilkington CA. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol. 2009. 21(6):575–80.
4. Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. 2004;140(3):365–6.
5. Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcifi cation in childhood dermatomyositis. Am J Roentgenol. 1984;142(2):397–400.
6. Urganus AL, Zhao YD, Pachman LM. Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum. 2009;61(4):501–8.
7. Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006;33(8):1691–3.
8. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington C A E ff ectiveness of infl iximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80.
9. Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986;5(4):527–30.
10. Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993; 20(9):558–660.
11. Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23(12):2152–5.
12. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763–6.
13. Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32(9):1837–9.
14. Terroso G, Bernardes M, Aleixo A, Madureira P, Vieira R, Bernardo A, Costa L. Therapy of calcinosis universalis complicating adult dermatomyositis. Acta Reumatol Port. 2013;38(1):44–8.
15. Martillotti J, Moote D, Zemel L. Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol. 2014;44(1):115–8.
16. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2009;77(1): 70–2.
17. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Eff ectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135–40.
18. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol. 1998;25(11):716–20.
19. Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis. 2010;13(3):e26–8.
20. Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol. 2009;60(6):1076–7.
21. Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcifi cation to intravenous immunoglobulin. Arch Dermatol. 2008;144(5):585–7.
22. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and effi cacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.
23. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150–62.
24. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961–78.
25. Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profi le (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S118–57.
26. Frese E, Brown M, Norton B. Clinical reliability of manual muscle testing: middle trapezius and gluteus medius muscles. Phys Ther. 1987;67(7):1072–6.
27. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005;34(6):805–12.
28. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6): 882–8.
29. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.
30. Pachman LM, Callen AM, Hayford J, Chung A, Sinacore J, Ramsey-Goldman R. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methyl prednisolone therapy. Arthritis Rheum. 1994;37(Suppl):S429.
31. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825–30.
32. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methyl prednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138–41.
33. Clynes R. IVIG therapy: interfering with interferon-gamma. Immunity. 2007;26(1):4–6.
34. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. Fc gamma RIII-dependent inhibition of interferon-gamma responses mediates suppressive eff ects of intravenous immunoglobulin. Immunity. 2007;26(1):67–78.